The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database ; volume:47 ; number:11 ; day:14 ; month:8 ; year:2024 ; pages:2671-2678 ; date:11.2024
Journal of endocrinological investigation ; 47, Heft 11 (14.8.2024), 2671-2678, 11.2024
- Creator
-
Caruso, I.
Di Gioia, L.
Di Molfetta, S.
Caporusso, M.
Cignarelli, A.
Sorice, G. P.
Laviola, L.
Giorgino, F.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40618-024-02441-z
- URN
-
urn:nbn:de:101:1-2501012109007.755442890436
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Caruso, I.
- Di Gioia, L.
- Di Molfetta, S.
- Caporusso, M.
- Cignarelli, A.
- Sorice, G. P.
- Laviola, L.
- Giorgino, F.
- SpringerLink (Online service)
Other Objects (12)
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617
Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system